Acurx Pharmaceuticals, Inc. (ACXP)
Pre-market:
| Previous close | 1.8000 |
| Open | 1.9000 |
| Bid | 2.0700 x 100 |
| Ask | 2.1600 x 100 |
| Day's range | 1.8040 - 2.1300 |
| 52-week range | 1.1700 - 8.8200 |
| Volume | |
| Avg. volume | 108,700 |
| Market cap | 33.563M |
| Beta (5Y monthly) | -1.90 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the fourth quarter and full year ended December 31, 2023.
- PR Newswire
Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its fourth quarter and full year 2023 financial results on Monday, March 18, 2024, at 8:00 am ET before the U.S. financial markets open.
- PR Newswire
Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that an EOP2 meeting has been granted by FDA to discuss the overall Phase 3 clinical and non-clinical development plan to support an NDA (New Drug Application) filing for ibezapolstat for the treatment of CDI. The Company submitted its Meeting Request earlier this month follo
